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Punica granatum is commonly used in Korea as a traditional medicine for the treatment of pathogenic bacteria. In this study,
we investigated the in vitro and in vivo antimicrobial activity of P. granatum peel EtOH extract (PGPE) against 16 strains of
Salmonella. The minimal inhibitory concentrations of PGPE were in the range of 62.5–1000x03BCgmL−1. In addition, the in vivo
antibacterial activity of the PGPE extract was examined in a S. typhimurium infection mouse model. Mice were initially infected
withS. typhimurium and then with PGPE. The extract was found to have signiﬁcant eﬀects on mortality and the numbers of viable
S. typhimurium recovered from feces. Although clinical signs and histological damage were rarely observed in the treated mice,
the untreated controls showed signs of lethargy and histological damage in the liver and spleen. Taken together, the results of this
study indicate that PGPE has the potential to provide an eﬀective treatment for salmonellosis.
1.Introduction
Salmonella enterica, which are Gram-negative bacterial
pathogens capable of infecting humans and animals, cause
signiﬁcant morbidity and mortality worldwide [1]. S. enter-
icaserovartyphimuriumisaclinicallyimportantintracellular
bacterial pathogen that causes food poisoning and gastroen-
teritis in millions of people worldwide each year [2]. The
Centers for Disease Control (CDC) estimates that there are
nearly 1.4 million food-borne Salmonella infections annually
intheUSA[3].Thisbacteriuminfectstheintestinaltractand
causes systemic infection of various organs such as the liver
and spleen [4].
Fluoroquinolones and tetracyclines are the antibiotics
most commonly used to treat Salmonella, and until recently
most strains were susceptible to these drugs. However, a
high incidence of Salmonella strains resistant to commonly
prescribed antibiotics has recently been reported in Korea
and other countries [5, 6], and the increased appearance of
antibiotic resistant strains of Salmonella further exacerbates
this problem [7]. One major concern to public health has
been the global dissemination of S. typhimurium Deﬁnitive
Type 104, which is commonly resistant to ﬁve or more
antimicrobial agents [8–11]. The rise in antibiotic-resistant
pathogens has led to the development of new therapeutic
agents that are eﬀective against these bacteria. Recently, there
has been considerable interest in the use of plant materials as
analternativemethodtocontrolpathogenicmicroorganisms
[12], and many compounds of plant products have been
shown to be speciﬁcally targeted against resistant pathogenic
bacteria [13].
Punica granatum, which belongs to the family of Puni-
caceae, is commonly known as pomegranate, grenade,
granats and punica apple [14]. Punica granatum has been
used extensively as a traditional medicine in many countries
[15] for the treatment of dysentery, diarrhea, helminthiasis,
acidosis, hemorrhage and respiratory pathologies [16, 17].
In addition, P. granatum is reported to have antioxidant2 Evidence-Based Complementary and Alternative Medicine
Table 1: List of Salmonella strains used in this study.
Strain Serotypes Origin Resistant antibiotics
JOL 380 S. typhi ATCC 19943 Human —
JOL 381 S. paratyphi A Human —
JOL 386 S. enteritidis Chicken —
JOL 387 S. typhimurium Cattle —
JOL 388 S. typhimurium Cattle —
JOL 389 S. typhimurium Pig AM, C, G, S, TIC
JOL 407 S. enteritidis Chicken —
JOL 408 S. typhimurium Pig —
JOL 409 S. dublin ATCC 39184 Cattle —
JOL 410 S. derby ATCC 6960 Pig —
JOL 411 S. choleraesuis ATCC 7001 Pig AM, SXT
JOL 419 S. gallinarum Chicken CF, G, SXT
JOL 420 S. gallinarum Chicken CF, CIP, NA
JOL 421 S. gallinarum Chicken G, NA, S
JOL 422 S. gallinarum Chicken —
JOL 423 S. gallinarum ATCC 9184 Chicken AM, AMC, C, G, S
AM, ampicillin; AMC, amoxicillin/clavulanic acid; C, chloramphenicol; CF,
cephalothin; G, sulﬁsoxazole; NA, nalidixic acid; S, streptomycin; SXT,
trimethoprim/sulfamethoxazole; TIC, ticarcillin.
[18, 19], anti-atherosclerotic [20, 21], antibacterial [22, 23]
andantiviral[24]properties.TheconstituentsofP.granatum
include gallocatechins, delphinidin, cyanidin, gallic acid,
ellagic acid, pelargonidin and sitosterol, which are very well
known for their therapeutic properties [25].
Punica granatum peel is used to treat infections found
in human sexual organs as well as mastitis, acne, folliculitis,
pile, allergic dermatitis, tympanitis, scalds, diarrhea, dysen-
teryandasanantioxidant[26].Inaddition,itisreportedthat
theextractsofP.granatumhaveantimicrobialactivityagainst
Salmonella [23]. However, to date, no studies regarding
the antimicrobial activity of P. granatum peels have been
conducted. Therefore, the goal of this study is to evaluate the
antimicrobialactivityoftheEtOHextractofP.granatumpeel
using various in vitro and in vivo models.
2. Methods
2.1. Bacterial Strains and Culture Medium. Salmonella typhi
(ATCC 19943), S. dublin (ATCC 39184), S. derby (ATCC
6960), S. choleraesuis (ATCC 7001) and S. gallinarum (ATCC
9184) were used in this study (Table 1). In addition, this
study included local isolates of S. enteritidis, S. typhimurium,
S. gallinarum and S. paratyphi A, which were provided
by the National Veterinary Research and Quarantine Ser-
vice, Republic of Korea. Bacterial strains were suspended
in Mueller Hinton broth (MHB, Difco, USA) and then
incubated at 37◦C for 20h. Mueller Hinton agar (MHA,
Difco) was used for the agar diﬀusion method and minimal
inhibitory concentration (MIC). Salmonella typhimurium
(JOL 389) was used for in vivo assays in mice.
2.2. Extraction of Plant Material. Punica granatum peel was
purchased from an Oriental drug store, Daehak Hanyakkuk
(Iksan, Korea), and then authenticated by Dr D.Y. Kwon.
A voucher specimen (no. 06-022) was deposited in the
Laboratory of Herbalogy, College of Pharmacy, Wonkwang
University, Iksan, Korea. Next, the P. granatum peel was air-
dried in the dark at room temperature and then ground into
a powder using a mechanical grinder. Approximately 500g
of the powdered materials were then boiled in 1500mLof
EtOH for 3h. The solvent was then removed under reduced
pressure in a rotary evaporator (N-1000S, EYELA, Japan)
and dissolved in water or 50% dimethyl sulfoxide (DMSO,
Sigma, USA) prior to use.
2.3. High-Performance Liquid Chromatography Analysis. The
High-performance liquid chromatography (HPLC) system
consisted of a Shimadzu LC-6A model (Shimadzu, Tokyo,
Japan), with a column of ODS-C18 (4.6 × 250mm, 5µm)
a n dad e t e c t i o no fS P D -6 A Vw i t has e n s i t i v i t yo f0 . 0 4A U F S
andawavelengthof254nm.Elutionwascarriedoutataﬂow
rate of 0.8mL/min under a linear gradient of acetonitrile
(solvent A) and H2Ow i t h1 %f o r m i ca c i d( s o l v e n tB )f r o m
5% A to 100% A in 50min. The P. granatum peel EtOH
extract (PGPE) was dissolved in a mixture of methanol and
water (6 : 4vv−1), and 20µlL was injected into the HPLC.
The presence of gallic acid and ellagic acid was conﬁrmed by
the same retention time of their standards (Sigma Chemical
Co, St Louis, USA) (Figure 1). The obtained chromatogram
is shown in Figure 2 [27].
2.4. Antimicrobial Resistance Testing. The resistance of the
various Salmonella strains to diﬀerent antimicrobial agents
was determined using the disk-agar method standardized by
the Clinical and Laboratory Standards Institute [28]. The
quality control strain used was Enterococcus faecalis ATCC
29212.
2.5. Disc Diﬀusion Method. The antibacterial activities of
the isolates on the diﬀerent extracts were tested using the
disk-agar method described by the Clinical and Laboratory
Standards Institute Standards and by using a modiﬁed agar-
well diﬀusion method [28, 29]. Brieﬂy, sterile paper discs
(6mm; Toyo Roshi Kaihsa, Japan) were loaded with 20µL
of PGPE (varying concentrations: 100, 200 and 500µg)
dissolved in 50% DMSO and then left to dry for 18h at
37◦C in a sterile room. The bacterial suspensions were then
diluted to a turbidity of approximately 0.5 McFarland (∼1.5
× 108 CFUmL−1), and then further diluted to obtain the
ﬁnal inoculum. Next, the MHA was poured into Petri dishes
andinoculatedwith100µlLofthesuspensioncontaining1 ×
105 CFUmL−1 of bacteria. Ampicillin (Sigma Chemical Co)
was used as the positive control and discs treated with 50%
DMSO were used as the negative control. The plates were
thenplacedinanincubator(VisionCo,Seoul,Korea)at37◦C
for 24h, after which the diameter of the zone of inhibition
around each of the discs was measured and recorded. Each
experiment was performed in triplicate.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: The chemical structure of punicalagin (a), ellagic acid (b)
and gallic acid (c).
2.6. Determination of MICs. The MIC values were deter-
mined for microorganisms that were found to be sensitive
to PGPE during the disc diﬀusion assay. To accomplish
this, the microorganism inocula were prepared from 12-
h broth cultures and the suspensions were then adjusted
to a turbidity of 0.5 McFarland. Susceptibility tests were
then conducted using the standard broth micro dilution
method in accordance with the CLSI guidelines [30]i n
MHB with an inoculum of ∼5 × 104 CFUmL−1. The MHB
was then supplemented with serial dilutions of P. granatum
peel of EtOH extracts ranging from 3.9 to 2000µgmL −1
and ampicillin concentration was ranging from 0.03 to
250µgm L −1. The lowest concentration of PGPE capable of
inhibiting visible growth after 24h of incubation at 37◦Cw a s
then recorded as the MIC [30].
2.7. Animals. Mice were obtained from Da Mool Science
(Deajeon, Korea). All mice experiments in this study were
approved by the Wonkwang University Animal Ethics Com-
mittee in accordance with the guidelines of the Korean
Council on Animal Care. Fifteen male Balb/c mice (15–
17g) aged between 5 and 6 weeks were used for all in vivo
experiments. They were kept in a temperature-controlled
room under a 12h light 12h dark cycle. Animals had free
access to commercial solid food (SCF Co. Ltd, Korea) and
water ad libitum, and were acclimatized for at least 1 week
prior to beginning the experiments.
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Figure 2: HPLC analysis of PGPE (a) and 3D HPLC analysis (b).
(1) and (2) punicalagin isomers; (3) gallic acid; (4) ellagic acid.
2.8. In Vivo Assay Using Mice. Mice were divided into the
following groups: control (CON), Salmonella-infected (SI)
and Salmonella-infected + PGPE (SIPG). Each treatment
group contained ﬁve mice. Throughout the experiment,
mice were provided with water that contained streptomycin
(5mgmL−1) in order to reduce the level of facultative anaer-
obic bacteria that normally colonize the mouse intestine
[31]. The inhibition of the growth of test organisms in mice
was then determined by monitoring S. typhimurium in the
feces of the mice. Brieﬂy, S. typhimurium (JOL 389) was
grownovernightinLuria–Bertanibroth(Difco),centrifuged,
washed in phosphate-buﬀered saline (PBS) and then diluted
into 20% sucrose to achieve a ﬁnal concentration of 1 ×
105 CFU. The SI and SIPG groups exclusively were then
inoculated using gavage needle orally with approximately
105 CFU of S. typhimurium in a 0.1mL volume. One hour
after infection, animals in the SIPG group were orally
administered 5mg (using gavage needle) of the PGPE daily,
whereas CON and SI animals were not. Fecal samples
were then collected 0, 1, 2, 3, 4, 5 and 6 days after the
bacterial suspensions were administered and the numbers
of the bacteria per gram of feces were determined. Aliquots
(100µl) of fecal suspensions were serially diluted in PBS
and then plated on duplicate Salmonella-Shigella agar plates
(Difco), which were subsequently incubated overnight at
37◦C. Typical colonies were then counted on plates that
contained between 30 and 300 colonies [32], after which
conﬁrmation of S. typhimurium was performed by a PCR4 Evidence-Based Complementary and Alternative Medicine
Table 2: Antimicrobial activity (as inhibition zone diameters) of PGPE and ampicillin (APCL) against 16 strains of Salmonella.
Strain Serotypes
Diameter of clear zone (mm)
PGPE APCLa
100µg 200µg 500µg1 0 µg
JOL 380 S. typhi ATCC 19943 13.3 ± 1.1 16.3 ± 1.5 17.3 ± 1.1 34.2 ± 1.0
JOL 381 S. paratyphi A 14.3 ± 0.5 15.6 ± 1.1 18.6 ± 1.1 28.5 ± 1.1
JOL 386 S. enteritidis 9.0 ± 1.0 12.6 ± 1.5 14.3 ± 1.1 31.1 ± 0.3
JOL 387 S. typhimurium 9.6 ± 0.5 11.6 ± 0.5 14.6 ± 0.5 27.5 ± 1.0
JOL 388 S. typhimurium 11.0 ± 1.0 14.0 ± 1.0 15.0 ± 1.0 26.0 ± 1.0
JOL 389 S. typhimurium 9.0 ± 1.0 12.0 ± 1.0 12.6 ± 0.5 ND
JOL 407 S. enteritidis 9.3 ± 1.1 12.3 ± 0.5 14.6 ± 0.5 26.7 ± 1.2
JOL 408 S. typhimurium 8.6 ± 1.1 10.6 ± 0.5 14.0 ± 2.0 30.2 ± 0.5
JOL 409 S. dublin ATCC 39184 8.0 ± 0.0 10.0 ± 0.0 13.3 ± 0.5 27.0 ± 1.1
JOL 410 S. derby ATCC 6960 10.0 ± 0.0 12.0 ± 0.0 14.3 ± 0.5 25.6 ± 1.1
JOL 411 S. choleraesuis ATCC 7001 11.6 ± 0.5 15.6 ± 1.0 16.0 ± 0.0 11.2 ± 1.0
JOL 419 S. gallinarum 12.3 ± 0.5 16.0 ± 1.0 16.6 ± 1.1 27.3 ± 1.5
JOL 420 S. gallinarum 16.0 ± 0.0 16.0 ± 0.7 17.6 ± 0.5 25.8 ± 1.1
JOL 421 S. gallinarum 11.3 ± 0.5 15.0 ± 0.0 16.3 ± 0.5 25.2 ± 0.3
JOL 422 S. gallinarum 12.0 ± 0.0 14.0 ± 1.7 16.0 ± 1.0 28.5 ± 0.5
JOL 423 S. gallinarum ATCC 9184 7.6 ± 0.5 10.0 ± 0.0 13.3 ± 1.1 ND
Data shown represent the mean ± SE of three experiments that consisted of three replicates. ND, No activity detected.
aPositive control.
assay using a previously described method [33]. At Day 4
post-infection,themiceweresacriﬁced,andtissuespecimens
of the kidney, liver, intestine and spleen organs were trans-
ferred to 10% buﬀered neutral formalin for histopathologic
examinations and then processed using standard procedures.
Sectionsofparaﬃn-embeddedtissueswerethenstainedwith
hematoxylin and eosin.
3. Results
3.1. Determination of Antibacterial Activity by the Disc Dif-
fusion Method. The antimicrobial eﬃcacy of PGPE against
the 16 Salmonella strains was evaluated by the disc diﬀusion
method via determination of the surrounding zones of
inhibition, as well as by evaluating the MIC using the agar
dilution method. Table 2 shows the antimicrobial activity
of P. granatum peel extract as determined by the disc
diﬀusionmethod.Themeanvaluesofthezonesofinhibition
produced against the tested bacteria ranged from 13.3 to
18.6mm, with the growth of each of the tested strains being
inhibited at 500µg per disc and the zone of inhibition
increasing in a dose-dependant manner.
3.2. Determination of MICs. The MICs of the PGPE against
the 16 strains of Salmonella are shown in Table 3.T h eM I C s
determined using the broth dilution method conﬁrmed the
results obtained using the disc diﬀusion method. PGPE
showed antimicrobial activity against each of the tested
strains, and these values ranged from 62.5 to 1000µgmL −1.
The in vivo experiment was therefore conducted with the
EtOH extract.
Table 3: Antimicrobial activity of PGPE and ampicillin (APCL)
against 16 strains of Salmonella.
Strain Serotypes MIC (µgmL −1)
PGPE APCLa
JOL 380 S. typhi ATCC 19943 250 0.97
JOL 381 S. paratyphi A 62.5 1.95
JOL 386 S. enteritidis 1000 1.95
JOL 387 S. typhimurium 1000 1.95
JOL 388 S. typhimurium 500 0.97
JOL 389 S. typhimurium 250 >250
JOL 407 S. enteritidis 250 1.95
JOL 408 S. typhimurium 500 1.95
JOL 409 S. dublin ATCC 39184 500 0.97
JOL 410 S. derby ATCC 6960 500 1.95
JOL 411 S. choleraesuis ATCC 7001 62.5 >250
JOL 419 S. gallinarum 62.5 1.95
JOL 420 S. gallinarum 62.5 1.95
JOL 421 S. gallinarum 125 1.95
JOL 422 S. gallinarum 250 1.95
JOL 423 S. gallinarum ATCC 9184 1000 >250
aPositive control.
3.3. Antibacterial Eﬃcacy of PGPE in Mice. The in vivo
antibacterial activity of PGPE was examined using a mouse
S. typhimurium infection model. Brieﬂy, mice were infected
with 1 × 105 CFU of S. typhimurium (SI). One-hour later,Evidence-Based Complementary and Alternative Medicine 5
Table 4: Eﬀects of treatment with PGPE on fecal shedding of S. typhimurium (CFU g−1)b ym i c e .
Group Day of post-feeding
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
SI-1 0 3 × 103 2 × 103 1 × 104 2 × 104 1 × 104 Death
SI-2 0 2 × 104 5 × 104 7 × 105 Death Death Death
SI-3 0 3 × 104 1 × 105 2 × 105 Death Death Death
SI-4 0 7 × 104 3 × 104 2 × 104 1 × 106 Death Death
SI-5 0 4 × 105 2 × 105 1 × 105 3 × 106 Death Death
SIPG-1 0 1 × 103 1 × 103 1 × 103 6 × 103 2 × 103 0
SIPG-2 0 2 × 103 1 × 103 2 × 103 3 × 103 2 × 103 2 × 103
SIPG-3 0 2 × 102 2 × 103 8 × 103 3 × 103 3 × 102 2 × 102
SIPG-4 0 1 × 103 3 × 102 2 × 102 1 × 102 3 × 102 2 × 102
SIPG-5 0 4 × 102 8 × 102 1 × 103 2 × 102 3 × 102 1 × 102
Balb/c
mouse
Balb/c
mouse
Mouse infused with
S. typhimurium
Mouse infused with
S. typhimurium
Splean: hemorrhagic
necrosis
Death after 6 days
Liver & spleen: normal
Liver: necrosis
Mouse infused with
EtOH extract of Punica
granatum peel
Survival
after 6 days
Figure 3: Importance of PGPE against S. typhimurium infection.
the mice were orally administered PGPE (SIPG). As shown
in Table 4, treatment with the extract of P. granatum peel
was found to have marked eﬀects on mortality and on the
number of viable S. typhimurium recovered from feces. At
Day 1 post-infection, ten mice in the SI and SIPG group shed
viable S. typhimurium in feces, with the feces of mice in the
SI group being found to contain bacteria at a concentration
of 3 × 103 to 4 × 105 CFUg−1 and feces of mice in the SIPG
group being found to contain bacteria at a concentration of
2 × 102 to 2 × 103 CFUg−1. In addition, at Day 6 post-
injection, none of the mice in the SIPG group had died,
whereas all ﬁve mice in the SI group had succumbed as
illustrated in Figure 3.
3.4. Organ Histopathologic Changes. Salmonella typhimu-
rium-infected mice that did not receive the PGPE were
lethargic and showed signs of histological damage in the
liver and spleen. In addition, the central and portal veins of
the liver showed congestion with focal necrotic emboli-like
materials (Figure 4). There were multiple small necrotizing
nodular lesions in the liver parenchyma with Kuﬀer cell
hyperplasia and inﬂammatory cell inﬁltrate. The spleen
showed extensive hemorrhagic necrosis in the red pulp with
multiple apoptotic bodies in the white pulp (Figure 4). No
speciﬁc abnormal ﬁndings were observed in the kidney or
the small intestine. Conversely, clinical signs and histological
damage were rarely observed in S. typhimurium-infected
mice fed with the PGPE.
4. Discussion
Recently, a number of antibiotics have lost their eﬀectiveness
due to the development of resistant strains of bacteria, which
has primarily occurred through the expression of resistance
genes [34, 35]. In addition to inducing resistance, antibiotics
are sometimes associated with opposing eﬀects such as
hypersensitivity, immune-suppression and allergic reactions
[36]. Therefore, there is a need to develop alternative
antimicrobial drugs for the treatment of infectious diseases
[37, 38].
In the present study, the PGPE exhibited antibacterial
activity against all 16 strains of eight diﬀerent Salmonella
serotypes tested. In addition, the results of the MIC assays
also conﬁrmed its antibacterial eﬀects against all tested
salmonella strains. The PGPE also exhibited antibacterial
activities against Salmonella strains JOL 389, JOL 411, JOL6 Evidence-Based Complementary and Alternative Medicine
CON-A
SI-A
SIPG-A
CON-B
SI-B
SIPG-B
Figure 4: Histopathological changes in organs in CON, SI and SIPG. (a) spleen (×200) and (b) liver (×200).
419, JOL 420, JOL 421 and JOL 423, all of which have been
shown to be resistant to two to ﬁve antibiotics (Table 1).
The in vivo antibacterial assay also revealed that the extract
eﬀectively inhibited the growth of S. typhimurium and sig-
niﬁcantly reduced mouse mortality (Table 4). Furthermore,
clinicalsignsofinfectionandhistologicaldamagewererarely
observed in test mice, whereas untreated SI mice showed
severe clinical signs and histological damage in the tested
organs. This is the ﬁrst study describing the antibacterial
activity of P. granatum peel extract against Salmonella.B a s e d
on these promising in vitro and in vivo assay ﬁndings, we
believe that P. granatum peel extract is likely to become
a novel antimicrobial treatment for salmonellosis. It has
been reported that P. granatum peel extracts have shown
antibacterial activity against Escherichia coli O157 and
methicillin-resistant Staphylococcus aureus bacteria [14, 39].
This antibacterial activity may be indicative of the presence
of several metabolic toxins or broad-spectrum antibiotics.
Several metabolites from herb species, including alkaloids,
tannins and sterols, have previously been associated with
antimicrobial activity [40].
In order to investigate components from the PGPE, the
HPLC analysis was performed as shown in Figures 2(a)
and 2(b). This HPLC analysis among some other minor
constituents mainly shows some major phenolic compounds
[26]; gallic acid and ellagic acids in addition to punicalagin
as a major ellagitannin. The retention time shows it to be
gallic acid and ellagic acid [41, 42] and also the presence of
punicalaginisomers(Figure 1)couldbededucedtobeoneof
the major components from the results of literature reported
previously[27].Gallicacidwasreportedtohaveantibacterial
activity against some intestinal bacteria [43], ellagic acid has
anti-microbial activity [44] and punicalagin was reported
to show anti-food-borne pathogens [45] .T h es i t ea n dt h e
number of hydroxyl groups on the phenol components
may increase the toxicity against the microorganisms [46].
However, it has been reported that gallic acid, ellagic acid
and punicalagin have weak antibacterial activity against
Salmonella.
The antibacterial activity of P. granatum peel extract
might be related to the action of its antibiotic compounds
or to the presence of metabolic toxins. This suggests that
these components may also provide antibacterial activity
against Salmonella and provide a plausible explanation for
the higher antibacterial activity of the EtOH extract. On the
other hand, the unknown minor components present have
not been elucidated in terms of their activity. Further studies
then need to be done. In the future, thorough investigation is
needed to better ascertain the antibacterial eﬀect of this herb
extract.Evidence-Based Complementary and Alternative Medicine 7
Funding
Grant No. RTI 05-03-02 from the Regional Technology
Innovation Program of the Ministry of Commerce, Industry
and Energy (MOCIE) in Republic of Korea.
References
[1] S. L. Fink and B. T. Cookson, “Pyroptosis and host cell death
responses during Salmonella infection,” Cellular Microbiology,
vol. 9, no. 11, pp. 2562–2570, 2007.
[2] G. A. Grassl, Y. Valdez, K. S. B. Bergstrom, B. A. Vallance,
and B. B. Finlay, “Chronic enteric Salmonella infection
in mice leads to severe and persistent intestinal ﬁbrosis,”
Gastroenterology, vol. 134, no. 3, pp. 768–780, 2008.
[3] P. S. Mead, L. Slutsker, V. Dietz et al., “Food-related illness and
death in the United States,” Emerging Infectious Diseases, vol.
5, no. 5, pp. 607–625, 1999.
[4] B.Coburn,G. A.Grassl,and B.B.Finlay, “Salmonella, the host
and disease: a brief review,” Immunology and Cell Biology, vol.
85, no. 2, pp. 112–118, 2007.
[5] S.-H. Choi, J. H. Woo, J. E. Lee et al., “Increasing incidence of
quinoloneresistanceinhumannon-typhoidSalmonellaenter-
ica isolates in Korea and mechanisms involved in quinolone
resistance,”JournalofAntimicrobialChemotherapy,vol.56,no.
6, pp. 1111–1114, 2005.
[ 6 ]J .E .S t e v e n s o n ,K .G a y ,T .J .B a r r e t t ,F .M e d a l l a ,T .M .C h i l l e r ,
and F. J. Angulo, “Increase in nalidixic acid resistance among
non-typhi Salmonella enterica isolates in the United States
from 1996 to 2003,” Antimicrobial Agents and Chemotherapy,
vol. 51, no. 1, pp. 195–197, 2007.
[7] M. K. Bhan, R. Bahl, and S. Bhatnagar, “Typhoid and
paratyphoid fever,” The Lancet, vol. 366, no. 9487, pp. 749–
762, 2005.
[8] W. A. Gebreyes, S. Thakur, P. R. Davies, J. A. Funk, and C.
Altier, “Trends in antimicrobial resistance, phage types and
integrons among Salmonella serotypes from pigs, 1997–2000,”
Journal of Antimicrobial Chemotherapy, vol. 53, pp. 997–1003,
2004.
[9] G. G. Perron, G. Bell, and S. Quessy, “Parallel evolution
of multidrug-resistance in Salmonella enterica isolated from
swine,” FEMS Microbiology Letters, vol. 281, no. 1, pp. 17–22,
2008.
[10] C. Poppe, K. Ziebell, L. Martin, and K. Allen, “Diversity
in antimicrobial resistance and other characteristics among
Salmonella typhimurium DT104 isolates,” Microbial Drug
Resistance, vol. 8, pp. 107–122, 2002.
[ 1 1 ]E .J .T h r e l f a l l ,L .R .W a r d ,J .A .F r o s t ,a n dG .A .W i l l s h a w ,
“Spread of resistance from food animals to man–the UK
experience,” Acta Veterinaria Scandinavica. Supplementum,
vol. 93, pp. 63–68, 2000.
[12] F. Aqil, M. S. Khan, M. Owais, and I. Ahmad, “Eﬀect ofcertain
bioactive plant extracts on clinical isolates of beta-lactamase
producing methicillin resistant Staphylococcus aureus,” Journal
of Basic Microbiology, vol. 45, pp. 106–114, 2005.
[13] A. Nostro, L. Cellini, S. Di Bartolomeo et al., “Eﬀects of
combining extracts (from propolis or Zingiber oﬃcinale) with
clarithromycin on Helicobacter pylori,” Phytotherapy Research,
vol. 20, no. 3, pp. 187–190, 2006.
[14] S. P. Voravuthikunchai, T. Sririrak, S. Limsuwan, T. Supawita,
T. Iida, and T. Honda, “Inhibitory eﬀects of active compounds
from Punica granatum pericarp on verocytotoxin production
by enterohemorrhagic Escherichia coli O157:H7,” Journal of
Health Science, vol. 51, no. 5, pp. 590–596, 2005.
[15] R. P. Singh, M. K. N. Chidambara, and G. K. Jayaprakasha,
“Studies on the antioxidant activity of pomegranate (Punica
granatum) peel and seed extracts using in vitro models,”
Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp.
81–86, 2002.
[16] D. Ricci, L. Giamperi, A. Bucchini, and D. Fraternale, “Antiox-
idant activity of Punica granatum fruits,” Fitoterapia, vol. 77,
no. 4, pp. 310–312, 2006.
[17] A. S´ anchez-Lamar, G. Fonseca, J. L. Fuentes et al., “Assessment
of the genotoxic risk of Punica granatum L. (Punicaceae)
whole fruit extracts,” Journal of Ethnopharmacology, vol. 115,
no. 3, pp. 416–422, 2007.
[18] A. Related, D. LinksHeber, N. P. Seeram et al., “Safety and
antioxidant activity of a pomegranate ellagitannin-enriched
polyphenol dietary supplement in overweight individuals
with increased waist size,” Journal of Agricultural and Food
Chemistry, vol. 55, pp. 10050–10054, 2007.
[19] H. S. Parmar and A. Kar, “Medicinal values of fruit peels from
Citrus sinensis, Punica granatum, and Musa paradisiaca with
respect to alterations in tissue lipid peroxidation and serum
concentration of glucose, insulin, and thyroid hormones,”
Journal of Medicinal Food, vol. 11, no. 2, pp. 376–381, 2008.
[20] M. Aviram, M. Rosenblat, D. Gaitini et al., “Pomegranate
juice consumption for 3 years by patients with carotid artery
stenosis reduces common carotid intima-media thickness,
blood pressure and LDL oxidation,” Clinical Nutrition, vol. 23,
pp. 423–433, 2004.
[21] H. S. Parmar and A. Kar, “Protective role of Citrus sinensis,
Musa paradisiaca, and Punica granatum peels against diet-
induced atherosclerosis and thyroid dysfunctions in rats,”
Nutrition Research, vol. 27, no. 11, pp. 710–718, 2007.
[22] L. C. Braga, J. W. Shupp, C. Cummings et al., “Pomegranate
extract inhibits Staphylococcus aureus growth and subsequent
enterotoxin production,” Journal of Ethnopharmacology, vol.
96, no. 1-2, pp. 335–339, 2005.
[23] S. Naz, R. Siddiqi, S. Ahmad, S. A. Rasool, and S. A. Sayeed,
“Antibacterial activity directed isolation of compounds from
Punica granatum,” Journal of Food Science, vol. 72, no. 9, pp.
M341–M345, 2007.
[24] J. Zhang, B. Zhan, X. Yao, Y. Gao, and J. Shong, “Antiviral
activity of tannin from the pericarp of Punica granatum L.
against genital Herpes virus in vitro,” Zhongguo Zhong yao za
zhi, vol. 20, no. 9, pp. 556–576, 1995.
[25] E. P. Lansky and R. A. Newman, “Punica granatum
(pomegranate) and its potential for prevention and treatment
of inﬂammation and cancer,” Journal of Ethnopharmacology,
vol. 109, no. 2, pp. 177–206, 2007.
[26] R. P. Singh, M. K. N. Chidambara, and G. K. Jayaprakasha,
“Studies on the antioxidant activity of pomegranate (Punica
granatum) peel and seed extracts using in vitro models,”
Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp.
81–86, 2002.
[27] H. M. Kwak, H. H. Jeong, B. H. Sohng et al., “Quantitative
analysis of antioxdants in Korea pomegranate Husk (Granati
pericarpium) cultivated in diﬀerent site,” Journal of the Korean
Society for Applied Biological Chemistry, vol. 48, pp. 431–434,
2005.
[28] Clinical and Laboratory Standards Institute. Performance
Standards for Antimicrobial Disk Susceptibility Tests.
Approved Standards. CLSI document M2-A7. Wayne, Pa,
USA, 2001.8 Evidence-Based Complementary and Alternative Medicine
[29] C.O.Okunji,C.N.Okeke,H.C.Gugnani,andM.M.Iwu,“An
antifungal spirostanol saponin from fruit pulp of Dracaena
mannii,” International Journal of Crude Drug Research, vol. 28,
no. 3, pp. 193–199, 1990.
[30] Clinical and Laboratory Standards Institute. Methods for
Dilution Antimicrobial Susceptibility Tests for Bacteria that
Grow Aerobically. Approved Standards. CLSI document M7-
A5. Wayne, Pa, USA, 2000.
[31] M. L. Myhal, D. C. Laux, and P. S. Cohen, “Relative colonizing
abilities of human fecal and K-12 stains of Escherichia coli in
the large intestines of streptomycin treated mice,” European
Journal of Clinical Microbiology, vol. 1, pp. 186–192, 1982.
[32] M.-H. Lee, H. A. Kwon, D.-Y. Kwon et al., “Antibacterial
activity of medicinal herb extracts against Salmonella,” Inter-
national Journal of Food Microbiology, vol. 111, no. 3, pp. 270–
275, 2006.
[ 3 3 ]J .A l v a r e z ,M .S o t a ,A .B .V i v a n c oe ta l . ,“ D e v e l o p m e n to fa
multiplex PCR technique for detection and epidemiological
typing of Salmonella in human clinical samples,” Journal of
Clinical Microbiology, vol. 42, no. 4, pp. 1734–1738, 2004.
[34] J. Davies, “Inactivation of antibiotics and the dissemination
of resistance genes,” Science, vol. 264, no. 5157, pp. 375–382,
1994.
[35] R. F. Service, “Antibiotics that resist resistance,” Science, vol.
270, no. 5237, pp. 724–727, 1995.
[36] I. Ahmad, Z. Mehmood, and F. Mohammad, “Screening
of some Indian medicinal plants for their antimicrobial
properties,” Journal of Ethnopharmacology, vol. 62, no. 2, pp.
183–193, 1998.
[37] A. Berahou, A. Auhmani, N. Fdil, A. Benharref, M. Jana,
and C. A. Gadhi, “Antibacterial activity of Quercus ilex bark’s
extracts,” Journal of Ethnopharmacology, vol. 112, no. 3, pp.
426–429, 2007.
[38] K. Salom˜ ao, P. R. S. Pereira, L. C. Campos et al., “Brazilian
propolis: correlation between chemical composition and
antimicrobial activity,” Evidence-Based Complementary and
Alternative Medicine, vol. 5, no. 3, pp. 317–324, 2008.
[39] T. D. B. Machado, I. C. R. Leal, A. C. F. Amaral, K. R. N.
Dos Santos, M. G. Da Silva, and R. M. Kuster, “Antimicrobial
ellagitanninofPunicagranatumfruits,”JournaloftheBrazilian
Chemical Society, vol. 13, no. 5, pp. 606–610, 2002.
[40] M. D. Leven, B. D. A. Vanden, T. Marten, A. Vilientmick,
and E. C. Lomweas, “Screening of higher plants for biological
activity,” Planta Medica, vol. 36, pp. 311–312, 1979.
[41] J. Lu, Y. Wei, and Q. Yuan, “Preparative separation of puni-
calagin from pomegranate husk by high-speed countercurrent
chromatography,” Journal of Chromatography B, vol. 857, no.
1, pp. 175–179, 2007.
[42] M. Aviram, N. Volkova, R Coleman et al., “Pomegranate
phenolics from the peels, arils, and ﬂowers are antiathero-
genic: studies in vivo in atherosclerotic apolipoprotein e-
deﬁcient (E0) mice and in vitro in cultured macrophages and
lipoproteins,” Journal of Agricultural and Food Chemistry, vol.
56, pp. 1148–1157, 2008.
[43] Y.-J. Ahn, C.-O. Lee, J.-H. Kweon, J.-W. Ahn, and J.-H. Park,
“Growth-inhibitory eﬀects of Galla Rhois-derived tannins on
intestinalbacteria,”JournalofAppliedMicrobiology,vol.84,no.
3, pp. 439–443, 1998.
[44] B. Thiem and O. Go´ sli´ nska, “Antimicrobial activity of Rubus
chamaemorus leaves,” Fitoterapia, vol. 75, no. 1, pp. 93–95,
2004.
[45] T. Taguri, T. Tanaka, and I. Kouno, “Antimicrobial activity of
10 diﬀerent plant polyphenols against bacteria causing food-
borne disease,” Biological and Pharmaceutical Bulletin, vol. 27,
no. 12, pp. 1965–1969, 2004.
[46] M. M. Cowan, “Plant products as antimicrobial agents,”
Clinical Microbiology Reviews, vol. 12, no. 4, pp. 564–582,
1999.